Vilin Bio Med Ltd Stock Price Today (NSE: VILINBIO)
Fundamental Score
Vilin Bio Med Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Vilin Bio Med Ltd share price today is ₹36.00, up +0.00% on NSE/BSE as of 8 February 2026. Vilin Bio Med Ltd (VILINBIO) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹29.58 (Cr). The 52-week high for VILINBIO share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 118.30x, VILINBIO is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 0.96% and a debt-to-equity ratio of 0.02.
Vilin Bio Med Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Vilin Bio Med Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Vilin Bio Med Share Price: A Conservative Value Investor's Perspective
The pharmaceutical sector, while generally defensive, demands meticulous due diligence. Generics face pricing pressure, and branded segments require continuous innovation. This analysis examines the "Vilin Bio Med share price" of ₹36.0 from a capital safety perspective, drawing on publicly available data as part of a broader 80-parameter fundamental audit verified by Sweta Mishra. The high PE ratio of 118.3 immediately raises concerns for a value investor prioritizing downside protection.
A critical metric for assessing capital allocation efficiency is Return on Capital Employed (ROCE). Vilin Bio Med Ltd's ROCE of 4.2% is significantly below what a conservative investor would typically seek. A low ROCE suggests the company struggles to generate substantial returns from its invested capital. This has a direct impact on the company's moat or competitive advantage. A strong moat usually implies higher profitability and pricing power, something that's not visibly present with such ROCE.
When evaluating pharmaceutical companies, management quality is paramount. Consider
Mankind Pharma Ltd, for instance. While this analysis does not directly compare financial performance, differences in management capabilities, capital allocation track records, and corporate governance practices often explain variations in shareholder returns over the long term. Vilin Bio Med Ltd's ROCE could be an indicator of management execution, requiring further scrutiny.In comparison to peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd, Vilin Bio Med Ltd's valuation, implied by the PE ratio, appears rich given its ROCE. A conservative approach necessitates a deep dive into the underlying drivers of profitability, specifically examining cost structures, pricing strategies, and product pipeline. The relatively low ROCE suggests limited scope for reinvestment and compounded growth, which, combined with a elevated PE, presents notable risk for investors prioritizing capital preservation.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vilin Bio Med Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VILINBIO across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Robust Profit Growth (25.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (115.14%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (63.89%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (0.96%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (4.20%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 118.30x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (-2.28% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-20.12% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Weak Interest Coverage (1.69x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-11.25 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Vilin Bio Med Ltd Financial Statements
Comprehensive financial data for Vilin Bio Med Ltd including income statement, balance sheet and cash flow
About VILINBIO (Vilin Bio Med Ltd)
Vilin Bio Med Ltd (VILINBIO) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹29.58 (Cr). Vilin Bio Med Ltd has delivered a Return on Equity (ROE) of 0.96% and a ROCE of 4.20%. The debt-to-equity ratio stands at 0.02, reflecting the company's capital structure. Investors tracking VILINBIO share price can monitor key metrics including P/E ratio, promoter holding of 63.89%, and quarterly earnings growth.
Company Details
VILINBIO Share Price: Frequently Asked Questions
What is the current share price of Vilin Bio Med Ltd (VILINBIO)?
As of 08 Feb 2026, 11:53 am IST, Vilin Bio Med Ltd share price is ₹36.00. The VILINBIO stock has a market capitalisation of ₹29.58 (Cr) on NSE/BSE.
Is VILINBIO share price Overvalued or Undervalued?
VILINBIO share price is currently trading at a P/E ratio of 118.30x, compared to the industry average of 31.77x. Based on this relative valuation, the Vilin Bio Med Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of VILINBIO share price?
The 52-week high of VILINBIO share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Vilin Bio Med Ltd share price?
Key factors influencing VILINBIO share price include quarterly earnings growth (Sales Growth: 115.14%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Vilin Bio Med Ltd a good stock for long-term investment?
Vilin Bio Med Ltd shows a 5-year Profit Growth of 6.58% and an ROE of 0.96%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.02 before investing in VILINBIO shares.
How does Vilin Bio Med Ltd compare with its industry peers?
Vilin Bio Med Ltd competes with major peers in the Pharmaceuticals. Investors should compare VILINBIO share price P/E of 118.30x and ROE of 0.96% against the industry averages to determine competitive standing.
What is the P/E ratio of VILINBIO and what does it mean?
VILINBIO share price has a P/E ratio of 118.30x compared to the industry average of 31.77x. Investors pay ₹118 for every ₹1 of annual earnings.
How is VILINBIO performing according to Bull Run's analysis?
VILINBIO has a Bull Run fundamental score of 33.7/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does VILINBIO belong to?
VILINBIO operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Vilin Bio Med Ltd share price.
What is Return on Equity (ROE) and why is it important for VILINBIO?
VILINBIO has an ROE of 0.96%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Vilin Bio Med Ltd generates profits from shareholders capital.
How is VILINBIO debt-to-equity ratio and what does it indicate?
VILINBIO has a debt-to-equity ratio of 0.02, which indicates conservative financing with low financial risk.
What is VILINBIO dividend yield and is it a good dividend stock?
VILINBIO offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Vilin Bio Med Ltd shares.
How has VILINBIO share price grown over the past 5 years?
VILINBIO has achieved 5-year growth rates of: Sales Growth -2.28%, Profit Growth 6.58%, and EPS Growth -20.12%.
What is the promoter holding in VILINBIO and why does it matter?
Promoters hold 63.89% of VILINBIO shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Vilin Bio Med Ltd.
What is VILINBIO market capitalisation category?
VILINBIO has a market capitalisation of ₹30 crores, placing it in the Small-cap category.
How volatile is VILINBIO stock?
VILINBIO has a beta of N/A. A beta > 1 suggests the Vilin Bio Med Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is VILINBIO operating profit margin trend?
VILINBIO has a 5-year average Operating Profit Margin (OPM) of 8.88%, indicating the company's operational efficiency.
How is VILINBIO quarterly performance?
Recent quarterly performance shows Vilin Bio Med Ltd YoY Sales Growth of 115.14% and YoY Profit Growth of 25.00%.
What is the institutional holding pattern in VILINBIO?
VILINBIO has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Vilin Bio Med Ltd stock.